How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34461270/

Given the lack of a gold standard, the clinical usefulness of Comprehensive Genomic Profiling (CGP) has not been established. This systematic review aimed to evaluate evidence about the clinical benefit...

BRD7 increases resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34477353/

doi: 10.23736/S0026-4806.21.07716-8. Online ahead of print. 1 Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. 2 Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary...

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34481329/

The ALI score is a powerful prognostic and predictive biomarker for patients with advanced NSCLC treated with PD-L1 inhibitors alone, but not in combination with chemotherapy. Its association with outcomes...

Viral Infection and Lung Cancer Immunotherapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34434887/

Immunotherapy with immune checkpoint inhibitors (mainly anti-PD1 and anti-PDL1 monoclonal antibodies) became a standard of care in non-small cell lung cancer (NSCLC) patients. Most of the clinical trials excluded patients...

Inhibition of miR-144-3p exacerbates non-small cell lung cancer progression by targeting CEP55 - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34435195/

Increasing evidence has indicated that microRNA dysregulation is closely related to the occurrence and development of cancers. Herein, we investigated the relationship between miR-144-3p and CEP55 expression. We then evaluated...